The soluble interleukin-2 receptor test measures circulating soluble CD25, a protein released mainly by activated T lymphocytes. It can be elevated in sarcoidosis and may be more sensitive than angiotensin-converting enzyme in some cohorts, but it is not specific enough to diagnose sarcoidosis alone. High levels also occur in lymphoma, leukemia, infection, autoimmune disease, hemophagocytic syndromes, and other states of intense immune activation. Kidney function and laboratory method can affect interpretation, and there is no universal cutoff that applies to every assay. In suspected sarcoidosis, the result is supportive only when the clinical and imaging pattern fits and alternative causes of granulomatous inflammation have been excluded. Diagnosis usually rests on a compatible presentation, nonnecrotizing granulomas in tissue when biopsy is needed, and careful exclusion of infections, occupational exposures, immune disorders, and malignancy.
- Soluble IL-2 receptor is also called sIL-2R or soluble CD25.
- A high result shows immune activation, not a sarcoidosis-specific process.
- The laboratory’s own reference interval must be used because assays and units differ.
- The test may support diagnosis or monitoring, but imaging, organ function, and biopsy carry more weight.
- Very high or rising levels with fever, weight loss, enlarged nodes, or abnormal blood counts require evaluation for lymphoma and other serious causes.
Table of Contents
- What Soluble IL-2 Receptor Measures
- What a High sIL-2R Result Means
- How the Test Fits Into Sarcoidosis Diagnosis
- Organ Involvement and Supporting Tests
- Other Causes of Elevated Soluble IL-2 Receptor
- Using sIL-2R to Monitor Disease
- Interpreting Results and Planning Next Steps
What Soluble IL-2 Receptor Measures
Interleukin-2 is a cytokine that helps regulate the growth, survival, and function of T lymphocytes. The high-affinity IL-2 receptor includes an alpha chain called CD25. Activated T cells express increased CD25 on their surface, and part of that receptor can be released into blood as soluble IL-2 receptor.
The serum test therefore acts as an indirect marker of cellular immune activation. It does not measure interleukin-2 itself, and it does not identify which antigen or disease activated the immune system. A high result means that immune cells are turning over or signaling more intensely than expected, but the source must be determined clinically.
The test usually requires a standard venous blood sample. Fasting is not normally necessary. Laboratories report values in units per milliliter, kilo-units per liter, picograms per milliliter, or another assay-defined unit. Reference intervals vary substantially. A cutoff from one publication cannot be applied safely to a report generated by another method.
Some reports use the name soluble CD25, sCD25, sIL-2R, or sIL-2Rα. These generally refer to the soluble alpha chain, although the exact assay should be confirmed. The result is not the same as CD25 expression measured on cells by flow cytometry.
Kidney function can influence the level because soluble proteins may accumulate when clearance declines. Age, inflammatory burden, treatment, and assay handling may also affect the number. Clinicians should compare results obtained with the same method whenever possible and interpret them beside creatinine and eGFR.
The test is not widely standardized across countries. In some health systems it is commonly used in sarcoidosis and hematologic practice; in others it is a specialized send-out test. Turnaround may range from days to more than a week.
Reference intervals can differ by several-fold because assays use different antibodies, calibrators, and molecular forms. One laboratory may flag a result above roughly 600 U/mL, while another uses a substantially different upper limit. These examples are not interchangeable. The correct interpretation is the patient’s value divided conceptually by that laboratory’s upper limit—not the raw number compared with a threshold from a paper.
Pre-analytical timing matters less than it does for rapidly fluctuating cytokines, but treatment and acute illness matter greatly. A sample collected during bacterial pneumonia or after several weeks of corticosteroids may not represent untreated sarcoidosis activity. The requisition should include treatment status and the reason for testing whenever possible.
What a High sIL-2R Result Means
A high soluble IL-2 receptor result indicates increased lymphocyte activation or turnover. The magnitude can help prioritize the differential diagnosis, but no concentration proves one disease.
In sarcoidosis, activated T cells gather in granulomas and affected organs. Serum sIL-2R often rises with greater inflammatory burden and multi-organ disease. Studies have reported useful sensitivity and specificity in selected referral populations, sometimes outperforming serum ACE. Those numbers depend on who was tested, the cutoff chosen, and which alternative diagnoses were included.
The positive predictive value is lower in a broad population because many conditions raise sIL-2R. A modest elevation in a patient with reduced kidney function or an acute infection may have little specificity. A marked elevation in a patient with bilateral hilar lymphadenopathy, uveitis, and biopsy-proven nonnecrotizing granulomas is more supportive of active sarcoidosis—but still not the diagnostic foundation.
Very high levels deserve deliberate evaluation for hematologic malignancy, particularly aggressive lymphoma or adult T-cell leukemia/lymphoma in relevant settings. The relationship is not absolute: severe inflammatory or infectious diseases can also produce large elevations, and some lymphomas show only modest values.
A normal result does not exclude sarcoidosis. Localized disease, inactive fibrotic disease, treated disease, and assay variation can all produce a value within range. A normal value should not overrule characteristic cardiac MRI, ocular examination, neurologic imaging, PET findings, or tissue pathology.
The result also does not distinguish active inflammation from permanent scar in every organ. In advanced pulmonary fibrosis, symptoms and reduced lung function may persist despite less immune activity. Conversely, clinically silent cardiac or neurologic inflammation can be dangerous even when a serum marker is not dramatically elevated.
How the Test Fits Into Sarcoidosis Diagnosis
Sarcoidosis diagnosis is built on three principles:
- A compatible clinical and radiologic presentation
- Nonnecrotizing granulomatous inflammation in tissue when biopsy is necessary
- Exclusion of alternative causes of granulomas or a similar organ pattern
No blood marker replaces these steps. The soluble IL-2 receptor test can strengthen or weaken suspicion, choose a biopsy target, or provide a baseline, but it cannot show that granulomas are sarcoidal rather than infectious, occupational, drug-related, immune-deficiency-related, or malignant.
Some presentations are so characteristic that biopsy may not be required, such as Löfgren syndrome with bilateral hilar lymphadenopathy, erythema nodosum, and ankle arthritis in the appropriate setting. In most atypical or organ-threatening presentations, tissue confirmation is valuable.
Biopsy site selection aims for the safest accessible tissue with the highest diagnostic yield. Skin lesions, peripheral lymph nodes, conjunctiva, or endobronchial and transbronchial sites may be considered. Endobronchial ultrasound-guided lymph-node sampling is commonly used for mediastinal or hilar adenopathy. Tissue should be evaluated not only for granulomas but also for infection and malignancy.
Tuberculosis, nontuberculous mycobacterial disease, fungal infection, beryllium disease, hypersensitivity pneumonitis, common variable immunodeficiency-related granulomatous disease, foreign-body reactions, lymphoma, and drug-induced sarcoid-like reactions are among the important alternatives. Exposure history and microbiologic testing are essential.
The ACE test is another supportive marker. ACE can be elevated in sarcoidosis but has limited sensitivity and specificity, is influenced by ACE-inhibitor treatment and genotype, and can rise in other granulomatous or metabolic conditions. sIL-2R may be more sensitive in some studies, but it shares the central limitation of nonspecific immune activation.
A useful approach is to ask whether the marker changes a decision. It may justify closer organ screening or support biopsy in an uncertain case. It should not be used to avoid biopsy when malignancy or infection remains plausible.
Neither sIL-2R nor ACE appears in the ATS guideline as a definitive diagnostic criterion. Their role is adjunctive. This matters when insurance, referral, or treatment decisions demand a firm diagnosis: a biomarker-positive patient still needs evidence that the clinical syndrome is sarcoidosis and that better explanations have been addressed.
Organ Involvement and Supporting Tests
Sarcoidosis is a multisystem disease, so the workup must assess organs rather than merely confirm that inflammation exists.
Lungs and lymph nodes: Chest radiography and high-resolution CT show hilar or mediastinal lymphadenopathy, perilymphatic nodules, parenchymal infiltrates, airway disease, or fibrosis. Pulmonary function tests measure restriction, airflow obstruction, and diffusion capacity. Serum sIL-2R may correlate with inflammatory burden but cannot replace imaging or physiology.
Eyes: Uveitis can threaten vision and may cause pain, redness, light sensitivity, floaters, or blurred vision. Some ocular disease is asymptomatic, so baseline ophthalmologic examination is often recommended after diagnosis.
Heart: Cardiac sarcoidosis can cause conduction block, ventricular arrhythmias, cardiomyopathy, or sudden death. Electrocardiography, ambulatory monitoring, echocardiography, cardiac MRI, and FDG-PET are used according to risk. A normal sIL-2R result cannot exclude cardiac involvement.
Nervous system: Neurosarcoidosis can affect meninges, cranial nerves, brain, spinal cord, or peripheral nerves. MRI and cerebrospinal fluid evaluation are usually required. CSF soluble IL-2 receptor has been studied, but available evidence is limited and overlap with infection and lymphoma remains important.
Calcium and kidneys: Granuloma macrophages can increase active vitamin D production, causing hypercalcemia, hypercalciuria, kidney stones, or kidney injury. Serum calcium, creatinine, eGFR, urinalysis, and sometimes urine calcium and vitamin D metabolites are assessed.
Liver, spleen, skin, and lymph nodes: Liver enzymes—especially alkaline phosphatase—may be abnormal. Skin lesions can provide accessible biopsy tissue. Splenomegaly, cytopenias, or widespread lymphadenopathy broaden the differential toward hematologic disease.
Baseline testing often includes a complete blood count, metabolic panel, calcium, creatinine, liver enzymes, urinalysis, ECG, chest imaging, and symptom-directed studies. The soluble IL-2 receptor result belongs within that organ map, not above it.
Other Causes of Elevated Soluble IL-2 Receptor
The differential diagnosis is broad because CD25 is released whenever T-cell activation or lymphoid-cell turnover is substantial.
Hematologic malignancy: Hodgkin and non-Hodgkin lymphomas, adult T-cell leukemia/lymphoma, and some leukemias can produce high levels. The result may correlate with tumor burden or prognosis in selected diseases, but diagnosis requires blood studies, imaging, flow cytometry, and tissue pathology.
Hemophagocytic lymphohistiocytosis: HLH can cause extreme immune activation with fever, cytopenias, liver dysfunction, high ferritin, splenomegaly, and elevated soluble CD25. sCD25 is part of established HLH diagnostic frameworks, but adult interpretation requires specialist assessment and other criteria.
Infection: Viral, bacterial, mycobacterial, fungal, and parasitic infections can activate T cells. Tuberculosis is particularly important when sarcoidosis is being considered because both can produce granulomas and lymph-node or lung abnormalities.
Autoimmune and inflammatory disease: Rheumatoid arthritis, systemic lupus erythematosus, vasculitis, inflammatory bowel disease, autoimmune hepatitis, and other disorders may elevate the marker. It does not identify which pathway is active.
Immune deficiency with granulomatous disease: Common variable immunodeficiency can produce granulomatous-lymphocytic interstitial lung disease and lymphadenopathy that resemble sarcoidosis. Immunoglobulin levels and infection history help distinguish it.
Drug-induced sarcoid-like reactions: Immune checkpoint inhibitors, interferons, tumor necrosis factor inhibitors in paradoxical cases, and other agents can trigger granulomatous reactions. Cancer progression, treatment reaction, infection, and sarcoidosis may overlap, making biopsy important.
Kidney dysfunction can amplify the measured concentration without being the primary inflammatory cause. The clinician should therefore review eGFR before attributing a modest rise to active sarcoidosis.
A high result should lead to targeted questions: Are there fevers or night sweats? Is weight loss rapid? Are blood counts abnormal? Is lactate dehydrogenase elevated? Are lymph nodes asymmetric, bulky, or rapidly growing? Is there an infection exposure? The answers determine the next test.
Using sIL-2R to Monitor Disease
Soluble IL-2 receptor often falls when active sarcoidosis improves with corticosteroids, methotrexate, tumor necrosis factor inhibition, or spontaneous remission. A baseline elevation can therefore provide a useful personal marker. The trend is more meaningful when the same assay is used and kidney function is stable.
It should not be the sole treatment target. Treatment in sarcoidosis is based on threat to organ function, symptoms, and risk of permanent damage. A patient with worsening cardiac conduction, vision, neurologic function, or pulmonary physiology needs action even if sIL-2R is unchanged. A persistently elevated result without clinical deterioration may not justify more immunosuppression.
Several situations can make the trend misleading:
- Corticosteroids suppress immune activation and lower the marker before structural recovery occurs.
- Progressive fibrosis may worsen lung function while inflammatory markers fall.
- Infection during immunosuppression may raise sIL-2R and mimic relapse.
- Declining kidney function may elevate the concentration.
- A switch in laboratory platform may create an apparent jump or drop.
- Lymphoma or another new disease may cause a rise unrelated to sarcoidosis.
Monitoring should be organ-specific. Pulmonary disease may require symptoms, spirometry, diffusion capacity, and imaging. Cardiac disease requires rhythm and imaging assessment. Eye disease requires direct examination. Neurosarcoidosis requires neurologic evaluation and often MRI. Calcium and kidney effects need laboratory follow-up.
Serum ACE, CRP, ESR, lysozyme, calcium, and other biomarkers may be followed, but none is universally reliable. Combining a biomarker trend with objective organ measurements is more informative than chasing normalization of every blood value.
Interpreting Results and Planning Next Steps
High sIL-2R with classic chest imaging and compatible biopsy: Supports active sarcoidosis. The next priority is screening for organ involvement and deciding whether treatment is needed.
High sIL-2R with bulky or asymmetric lymph nodes, cytopenias, or B symptoms: Sarcoidosis remains possible, but lymphoma, infection, and other causes require focused evaluation and often tissue diagnosis.
High sIL-2R with reduced eGFR: Determine how much kidney dysfunction may contribute and assess for renal sarcoidosis, hypercalcemia, obstruction, infection, or another kidney disease.
Normal sIL-2R with suspected cardiac, ocular, or neurologic sarcoidosis: Do not stop the workup. Organ-specific testing has greater sensitivity for dangerous localized disease.
Falling sIL-2R during treatment with stable or improving organ tests: Consistent with reduced immune activation, though treatment decisions should still use the complete clinical picture.
Rising sIL-2R during remission: Reassess symptoms, kidney function, infection, malignancy risk, medication changes, and assay method before calling it a relapse.
Patients should keep the exact result, units, reference interval, laboratory name, and date. Comparing a value of 1,200 U/mL with 1,200 pg/mL is not meaningful without knowing the assays.
Urgent evaluation is warranted for fainting, palpitations with dizziness, sustained rapid heartbeat, chest pain, new shortness of breath, sudden weakness, facial droop, seizures, severe headache with neurologic symptoms, or sudden visual change. Marked hypercalcemia can cause confusion, vomiting, dehydration, weakness, and abnormal heart rhythm and also requires prompt care.
The test is most useful when it answers a focused question: Does this pattern support active immune disease, and does the trend agree with the organs? It is least useful when treated as a universal screen or a stand-alone diagnosis.
References
- Enhanced Diagnosing Patients Suspected of Sarcoidosis Using a Novel Prediction Model. 2024. Peer-reviewed diagnostic study.
- Phenotypes and Serum Biomarkers in Sarcoidosis. 2024. Peer-reviewed review.
- Diagnostic Value of Soluble Interleukin-2 Receptor in Patients With Neurosarcoidosis: A Systematic Review. 2024. Systematic review.
- SACE and IL-2R as Serum Biomarkers for Evaluation of Multi-Organ Involvement and Prognosis of Sarcoidosis. 2023. Peer-reviewed cohort study.
- Role of Serum Soluble Interleukin-2 Receptor Level in the Diagnosis of Sarcoidosis. 2023. Peer-reviewed clinical study.
- Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline. 2020. Clinical practice guideline.
Disclaimer
This article is educational and does not replace specialist diagnosis or treatment. Soluble IL-2 receptor must be interpreted with the assay range, kidney function, symptoms, imaging, organ tests, microbiology, and biopsy. Seek urgent care for fainting, serious palpitations, chest pain, severe breathlessness, sudden neurologic or visual symptoms, seizures, or confusion.
